Irinotecan-Based Regimens for the Second-Line Treatment of Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A Monocentric Experience

被引：0
|
作者：
Bardasi, C. [1 ]
Caputo, F. [1 ]
Santini, C. [1 ]
Cerma, K. [1 ]
Gardini, Casadei A. [1 ]
Andrikou, K. [1 ]
Salati, M. [1 ]
Fontana, A. [1 ]
Spallanzani, A. [1 ]
Bertolini, F. [1 ]
Luppi, G. [1 ]
Gelsomino, F. [1 ]
机构：
[1] Univ Hosp Modena, Dept Oncol & Hematol, Modena, Italy
来源：
NEUROENDOCRINOLOGY | 2020年 / 110卷
关键词：
neuroendocrine carcinoma; irinotecan; survival; second line treatment; nec; chemotherapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H03
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [1] Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)
    Bardasi, C.
    Spallanzani, A.
    Luppi, G.
    Bertolini, F.
    Fontana, A.
    Salati, M.
    Caputo, F.
    Santini, C.
    Cerma, K.
    Dominici, M.
    Gelsomino, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 156 - 156
  • [2] EXTRAPULMONARY POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMAS (PDNEC) TREATED WITH CISPLATIN PLUS IRINOTECAN
    de Celis Ferrari, Anezka Rubin
    Braghiroli, Maria Ignez
    Bariani, Giovanni Mendonca
    Munhoz, Rodrigo Ranella
    Pfiffer, Tulio Eduardo
    Hoff, Paulo Marcelo
    Riechelmann, Rachel Pimenta
    ANNALS OF ONCOLOGY, 2011, 22 : v80 - v80
  • [3] Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
    Camilla Bardasi
    Andrea Spallanzani
    Stefania Benatti
    Francesca Spada
    Alice Laffi
    Lorenzo Antonuzzo
    Daniele Lavacchi
    Riccardo Marconcini
    Marco Ferrari
    Margherita Rimini
    Francesco Caputo
    Chiara Santini
    Krisida Cerma
    Andrea Casadei-Gardini
    Kalliopi Andrikou
    Massimiliano Salati
    Federica Bertolini
    Annalisa Fontana
    Massimo Dominici
    Gabriele Luppi
    Fabio Gelsomino
    Endocrine, 2021, 74 : 707 - 713
  • [4] Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
    Bardasi, Camilla
    Spallanzani, Andrea
    Benatti, Stefania
    Spada, Francesca
    Laffi, Alice
    Antonuzzo, Lorenzo
    Lavacchi, Daniele
    Marconcini, Riccardo
    Ferrari, Marco
    Rimini, Margherita
    Caputo, Francesco
    Santini, Chiara
    Cerma, Krisida
    Casadei-Gardini, Andrea
    Andrikou, Kalliopi
    Salati, Massimiliano
    Bertolini, Federica
    Fontana, Annalisa
    Dominici, Massimo
    Luppi, Gabriele
    Gelsomino, Fabio
    ENDOCRINE, 2021, 74 (03) : 707 - 713
  • [5] Efficacy of FOLFIRI as a second -line in extrapulmonary poorly differentiated neuroendocrine carcinoma
    Fabregat-Franco, Carles
    Munoz, M. Nieva
    Martin, F. Perez
    Ruffinelli, J.
    Vivas, C. Santos
    Sanchez, C.
    Salazar, R.
    Teule, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Irinotecan and oxaliplatin based regimens of second-line treatment in gastrointestinal neuroendocrine carcinoma (GI-NEC) patients: A retrospective study
    Zhang, J.
    Li, J.
    Lu, M.
    Shen, L.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 149 - 149
  • [7] Meta-analysis of irinotecan monotherapy versus irinotecan-based combined second-line therapy for the treatment of advanced gastric cancer
    Xu, Jia
    Zhang, Zi-Zhen
    Lin, Tian-Long
    Cao, Hui
    Yang, Han-Kwang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 13712 - +
  • [8] Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas - a single institution experience
    Goerner, M.
    Brasch, F.
    Hirnle, P.
    Gehl, H-B.
    Scholtz, L-U.
    Wegehenkel, K.
    Sudhoff, H.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (05) : 648 - 652
  • [9] Comparative Efficacy of 2nd-Line Chemotherapy Regimens in Extrapulmonary Poorly-Differentiated Neuroendocrine Carcinoma (PD NEC): The Mayo Clinic Experience
    McGarrah, P.
    Leventakos, K.
    Hobday, T.
    Molina, J.
    Finnes, H.
    Westin, G.
    Halfdanarson, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 155 - 155
  • [10] Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
    Cho, Yo-Han
    Yoon, So Young
    Kim, Soo-Nyung
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 255 - 262
12345